MX2019014427A - Forma cristalina de n-butildeoxigalactonojirimicina. - Google Patents
Forma cristalina de n-butildeoxigalactonojirimicina.Info
- Publication number
- MX2019014427A MX2019014427A MX2019014427A MX2019014427A MX2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A MX 2019014427 A MX2019014427 A MX 2019014427A
- Authority
- MX
- Mexico
- Prior art keywords
- crystalline form
- butyldeoxygalactonojirimycin
- triol
- piperidine
- hydroxymethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La invención se refiere a una forma cristalina de [(2R, 3S, 4R, 5S)-1-butil-2-(hidroximetil)-piperidina-3,4,5-triol, procesos para la preparación de la misma, composiciones farmacéuticas que contienen dicha forma cristalina, y su uso como medicamento, especialmente como inhibidor de la biosíntesis de glucolípidos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2017063287 | 2017-06-01 | ||
PCT/EP2018/064365 WO2018220131A1 (en) | 2017-06-01 | 2018-05-31 | Crystalline form of n-butyldeoxygalactonojirimycin |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019014427A true MX2019014427A (es) | 2020-02-05 |
Family
ID=62492649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019014427A MX2019014427A (es) | 2017-06-01 | 2018-05-31 | Forma cristalina de n-butildeoxigalactonojirimicina. |
Country Status (18)
Country | Link |
---|---|
US (2) | US11306058B2 (es) |
EP (1) | EP3630725A1 (es) |
JP (2) | JP6937850B2 (es) |
KR (1) | KR102612650B1 (es) |
CN (1) | CN110799497A (es) |
AU (1) | AU2018278247B2 (es) |
BR (1) | BR112019025125A2 (es) |
CA (1) | CA3065147A1 (es) |
CL (1) | CL2019003478A1 (es) |
EA (1) | EA201992807A1 (es) |
IL (1) | IL270961A (es) |
MA (1) | MA48944A (es) |
MX (1) | MX2019014427A (es) |
MY (1) | MY201196A (es) |
PH (1) | PH12019502635A1 (es) |
TW (1) | TWI770184B (es) |
UA (1) | UA125938C2 (es) |
WO (1) | WO2018220131A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3065147A1 (en) * | 2017-06-01 | 2018-12-06 | Idorsia Pharmaceuticals Ltd | Crystalline form of n-butyldeoxygalactonojirimycin |
US20220411371A1 (en) | 2019-09-25 | 2022-12-29 | Teva Pharmaceuticals International Gmbh | Solid state forms of lucerastat and process for preparation thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992000277A1 (fr) * | 1990-06-29 | 1992-01-09 | Nippon Shinyaku Co., Ltd. | Derive de piperidine |
US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
GB0229476D0 (en) | 2002-12-17 | 2003-01-22 | Oxford Glycosciences Uk Ltd | Novel process |
FR2861991B1 (fr) * | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
WO2006037069A1 (en) | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions |
EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
KR20080033463A (ko) | 2005-07-27 | 2008-04-16 | 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. | 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도 |
JP2009538276A (ja) | 2006-04-24 | 2009-11-05 | アカデミッシュ メディシュ セントラム | 嚢胞性線維症の改良型治療 |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
ITMI20122090A1 (it) | 2012-12-06 | 2014-06-07 | Dipharma Francis Srl | Sintesi di un inibitore delle glicosiltransferasi |
CA3065147A1 (en) * | 2017-06-01 | 2018-12-06 | Idorsia Pharmaceuticals Ltd | Crystalline form of n-butyldeoxygalactonojirimycin |
-
2018
- 2018-05-31 CA CA3065147A patent/CA3065147A1/en active Pending
- 2018-05-31 MA MA048944A patent/MA48944A/fr unknown
- 2018-05-31 MX MX2019014427A patent/MX2019014427A/es unknown
- 2018-05-31 EP EP18728624.0A patent/EP3630725A1/en active Pending
- 2018-05-31 KR KR1020197038894A patent/KR102612650B1/ko active IP Right Grant
- 2018-05-31 JP JP2019566190A patent/JP6937850B2/ja active Active
- 2018-05-31 US US16/618,036 patent/US11306058B2/en active Active
- 2018-05-31 UA UAA201912130A patent/UA125938C2/uk unknown
- 2018-05-31 AU AU2018278247A patent/AU2018278247B2/en active Active
- 2018-05-31 MY MYPI2019007035A patent/MY201196A/en unknown
- 2018-05-31 TW TW107118696A patent/TWI770184B/zh active
- 2018-05-31 CN CN201880035373.9A patent/CN110799497A/zh active Pending
- 2018-05-31 BR BR112019025125-1A patent/BR112019025125A2/pt active Search and Examination
- 2018-05-31 WO PCT/EP2018/064365 patent/WO2018220131A1/en active Application Filing
- 2018-05-31 EA EA201992807A patent/EA201992807A1/ru unknown
-
2019
- 2019-11-22 PH PH12019502635A patent/PH12019502635A1/en unknown
- 2019-11-27 IL IL270961A patent/IL270961A/en unknown
- 2019-11-28 CL CL2019003478A patent/CL2019003478A1/es unknown
-
2021
- 2021-08-31 JP JP2021140904A patent/JP7373529B2/ja active Active
- 2021-09-20 US US17/479,341 patent/US11713297B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL270961A (en) | 2020-01-30 |
CA3065147A1 (en) | 2018-12-06 |
TW201902876A (zh) | 2019-01-16 |
BR112019025125A2 (pt) | 2020-07-21 |
WO2018220131A1 (en) | 2018-12-06 |
JP6937850B2 (ja) | 2021-09-22 |
US20200140385A1 (en) | 2020-05-07 |
MA48944A (fr) | 2020-04-08 |
UA125938C2 (uk) | 2022-07-13 |
EP3630725A1 (en) | 2020-04-08 |
KR102612650B1 (ko) | 2023-12-11 |
MY201196A (en) | 2024-02-09 |
JP7373529B2 (ja) | 2023-11-02 |
US11306058B2 (en) | 2022-04-19 |
CL2019003478A1 (es) | 2020-06-05 |
AU2018278247B2 (en) | 2022-07-28 |
TWI770184B (zh) | 2022-07-11 |
JP2021185184A (ja) | 2021-12-09 |
US20220002245A1 (en) | 2022-01-06 |
EA201992807A1 (ru) | 2020-05-20 |
PH12019502635A1 (en) | 2020-07-13 |
US11713297B2 (en) | 2023-08-01 |
AU2018278247A1 (en) | 2020-01-16 |
KR20200011992A (ko) | 2020-02-04 |
JP2020521796A (ja) | 2020-07-27 |
CN110799497A (zh) | 2020-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12018500425A1 (en) | Novel 6-6 bicyclic aromatic ring substituted nuceloside analogues for use as prmt5 inhibitors | |
MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
WO2015160843A8 (en) | Ion channel activators and methods of use | |
MX2020005944A (es) | Analogos espirobiciclicos novedosos. | |
MX2017014035A (es) | Formas solidas novedosas. | |
PH12019500731A1 (en) | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors | |
PH12018500377A1 (en) | Novel annelated benzamides | |
PH12017501397B1 (en) | (2s, 4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor | |
EA201992542A1 (ru) | Фармацевтическая композиция для местного применения, содержащая, по меньшей мере, амитриптилин, для лечения периферической нейропатической боли | |
PH12018500378A1 (en) | Novel annelated phenoxyacetamides | |
EP4066835A4 (en) | USE OF A COMPOSITION FOR INCREASE ANTI-CANCER EFFECT HAVING A GAMMA INHIBITOR AS THE ACTIVE INGREDIENT | |
MX2019012454A (es) | Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol. | |
PH12017501444A1 (en) | (2r,4r)-5-(5`-chloro-2`-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid | |
SG11201907472QA (en) | Composition for inhibiting myofibrosis | |
PH12019502635A1 (en) | Crystalline form of n-butyldeoxygalactonojirimycin | |
WO2020127819A3 (en) | Pharmaceutical composition comprising apixaban | |
AU2018246257A8 (en) | Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol | |
MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
EP3733212A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER METASTASIS IN THE LUNG WITH CHI3L1 INHIBITOR AS THE ACTIVE SUBSTANCE | |
MX2012002580A (es) | Compuesto antibacteriano novedoso de hidroxifenilo. | |
WO2017064635A3 (en) | Saroglitazar magnesium, compositions containing it, process for its preparation | |
EP4180048A4 (en) | PHARMACEUTICAL COMPOSITION CONTAINING A CER COMPOUND AS ACTIVE INGREDIENT | |
PH12018501895A1 (en) | Substituted nucleoside analogues for use as prmt5 inhibitors | |
TR201722304A2 (tr) | Oseltami̇vi̇r fosfatin farmasöti̇k kapsül kompozi̇syonlari | |
EP3750882A4 (en) | DIACYLGLYCERIN-LACTONE COMPOUND, PROCESS FOR THEIR PRODUCTION AND THIS IMMUNSTIMULATOR CONTAINING THE ACTIVE SUBSTANCE |